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1623Letters to the Editor / Metabolism Clinical and Experimental 57 (2008) 1622–1624Asymmetric dimethylarginine levels decrease because of
insulin infusion: is it an unexpected finding?
In their recent article, Eid et al [1] hypothesized that acute
infusion of insulin would increase asymmetric dimethylar-
ginine (ADMA) levels in a group of young men with mildly
elevated blood pressures. Their assumption was based on the
previous findings showing that patients with insulin
resistance (IR) had high ADMA levels [2,3]. In our previous
report on patients with chronic kidney disease, we also
measured high ADMA and insulin levels that were positively
correlated [4]. However, the association between insulin and
ADMA levels in these reports does not necessarily mean that
insulin itself is the cause of ADMA elevation. It is not the
insulin but the lack of insulin effect, namely, the presence of
IR, which probably has a role in the elevation of ADMA.
Dandona et al [5] have shown that insulin has significant
anti-inflammatory and vasodilatory properties. Insulin
increases the expression of endothelial nitric oxide synthase
[6] and the release of nitric oxide [7,8] from the vascular
endothelium in a dose-dependent manner. At this point, the
findings of Eid et al [1] complement the previous in vitro
reports and help us to understand the mechanism of the
beneficial effects of insulin on the vascular endothelium.
However, we should keep in mind that this study was
performed in young men with mildly elevated blood
pressures, who are most likely to be insulin sensitive. It is
well reported that IR is present only in half of the
hypertensive population [9]. In our previous studies, we
did not observe IR in young patients with new-onset,
uncomplicated hypertension [10-12]. Therefore, it would be
interesting to design a further study to investigate the effect
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Hypertens 2007;21:173-5.Author reply: phenotype of subjects with type 2 diabetes
mellitus may determine clinical response to chromium
supplementation
With interest, we read the article by Wang et al [1]
about trying to find a tool for selecting patients who
are responsive to chromium supplementation and those
who are not. We fully agree that it is important to be
able to have some kind of parameter by which you can
select patients who have a low chromium status, as
there are no possibilities yet to define someone as
chromium deficient [2]. This would indeed be more
appropriate than performing more and more randomized
controlled trials in unselected patients in whom it seems
that, in most high-quality trials, there were no beneficial
effects [3].
However, there are some important points that need
clarification to be able to interpret the results accurately.
Firstly, the dependent variable used in this article is the
difference between insulin sensitivity measured at the end
and beginning of the 6-month study. The only subject
variable significantly associated with this difference is the
baseline insulin sensitivity. It is not surprising that this
baseline variable is associated with a change of the same
variable. We would like the authors to clarify this. It would
be perhaps more informative to know if patients who were
relatively more insulin resistant at baseline had a more
1624 Letters to the Editor / Metabolism Clinical and Experimental 57 (2008) 1622–1624beneficial effect on hemoglobin A1c and if this was
more pronounced in the chromium group than in the
placebo group.
Secondly, we would like to ask the authors to look beyond
their results. How would they advice researchers (and
clinical physicians) performing future human chromium
research to select patients? If it will be concluded from future
research that chromium has beneficial effects in specific
subgroups of subjects with type 2 diabetes mellitus, we
would like to select such patients in daily routine outpatient
care, which would not likely include insulin clamp
procedures. Would their results be the same when using a
homeostasis model assessment equation?
Nanne Kleefstra
Diabetes Centre, Isala Clinics, Zwolle, The Netherlands
Langerhans Medical Research Group, The Netherlands
E-mail address: kleefstra@langerhans.com
Sebastiaan T. Houweling
Langerhans Medical Research Group, The Netherlands
Huisartsenpraktijk Sleeuwijk, Sleeuwijk, The NetherlandsKlaas H. Groenier
Department of General Practice
University of Groningen, Groningen, The Netherlands
Henk J.G. Bilo
Diabetes Centre, Isala Clinics, Zwolle, The Netherlands
Department of Internal Medicine




[1] Wang ZQ, Qin J, Martin J, Zhang XH, Sereda O, Anderson RA, et al.
Phenotype of subjects with type 2 diabetes mellitus may determine
clinical response to chromium supplementation. Metabolism 2007;56:
1652-5.
[2] Kleefstra N, Houweling ST, Bilo HJ. Effect of chromium supplementa-
tion on glucose metabolism and lipids: a systematic review of
randomized controlled trials. Diabetes Care 2007;30:e102.
[3] Balk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG. Effect of
chromium supplementation on glucosemetabolism and lipids: a systematic
review of randomized controlled trials. Diabetes Care 2007;30:2154-63.
